Wilson Sonsini Goodrich & Rosati and Latham & Watkins advised CARGO Therapeutics, Inc. on the offering, and Cooley advised the underwriters. CARGO Therapeutics, Inc. (CARGO) (Nasdaq:CRGX)...
CARGO Therapeutics’ $281.3 Million Initial Public Offering
ZeroAvia’s Funding Round
Latham & Watkins advised ZeroAvia on the financing. ZeroAvia announced that Airbus, Barclays Sustainable Impact Capital, and NEOM have co-led the company’s latest financing round. Breakthrough...
Neumora Therapeutics’ $250.1 Million Initial Public Offering
Latham & Watkins advised Neumora, and Cooley advised the underwriters. Neumora Therapeutics, Inc. announced the pricing of its initial public offering of 14,710,000 shares of its common...
e.l.f. Beauty’s US$355 Million Acquisition of Naturium
Latham & Watkins advises e.l.f. Beauty in its acquisition of Naturium. e.l.f. Beauty (NYSE: ELF) has announced it has signed a definitive agreement to acquire Naturium,...
Ikena Oncology’s Acquisition of Pionyr Immunotherapeutics
Latham & Watkins advised Pionyr on the sale. Ikena Oncology, Inc. (Nasdaq: IKNA, Ikena) and Pionyr Immunotherapeutics, Inc. have announced the closing of Ikena’s acquisition of...
Revolution Medicines’ Acquisition of EQRx
Latham & Watkins advises Revolution Medicines on the deal, and Goodwin Procter advises EQRx. Revolution Medicines, Inc. (Nasdaq: RVMD) and EQRx, Inc. (Nasdaq: EQRX) announced a definitive agreement...
Cadence’s Acquisition of Rambus PHY IP Assets
Latham & Watkins advised Cadence, and Wilson Sonsini Goodrich & Rosati advised Rambus on the transaction. Cadence Design Systems, Inc. and Rambus Inc. announced that they have entered...
Figure’s $70 Million Series A Funding Round
Latham & Watkins represents Figure in the financing. Figure has announced the close of a $70 million Series A funding round. The round is led by...
NextRoll’s $50 Million Financing Deal From Capital IP
Latham & Watkins advises NextRoll in US$50 million financing deal from Capital IP. NextRoll, the San Francisco-based marketing technology company delivering products for ambitious marketers to...
Coherus BioSciences’ $57.5 Million Follow-On Offering
Latham & Watkins advised Coherus BioSciences, and Davis Polk advised J.P. Morgan Securities LLC and Citigroup Global Markets Inc. on the offering. Coherus BioSciences, Inc. (“Coherus”, Nasdaq:...
IDEAYA Biosciences’ $175 Million Common Stock Public Offering
Latham & Watkins represents IDEAYA Biosciences in the offering. IDEAYA Biosciences, Inc. (Nasdaq:IDYA) has announced the pricing of an underwritten public offering of common stock and...
Coinbase’s Acquisition of One River Digital Asset Management
Latham & Watkins represented Coinbase in the transaction. Coinbase announced that it has acquired One River Digital Asset Management (ORDAM). ORDAM will transition to become Coinbase Asset...